Overactive bladder (OAB), as defined by the International Continence Society, is 
characterized by a symptom complex including urinary urgency with or without 
urge incontinence, usually associated with frequency and nocturia. OAB syndrome 
has an incidence reported from six European countries ranging between 12-17%, 
while in the United States; a study conducted by the National Overactive Bladder 
Evaluation program found the incidence at 17%. In Asia, the prevalence of OAB is 
reported at 53.1%. In about 75%, OAB symptoms are due to idiopathic detrusor 
activity; neurological disease, bladder outflow obstruction (BOO) intrinsic 
bladder pathology and other chronic pelvic floor disorders are implicated in the 
others. OAB can be diagnosed easily and managed effectively with both 
non-pharmacological and pharmacological therapies. The first-line treatments are 
lifestyle interventions, bladder training, pelvic floor muscle exercises and 
anticholinergic drugs. Antimuscarinics are the drug class of choice for OAB 
symptoms; with proven efficacy, and adverse event profiles that differ somewhat.